HOMA-IR

Your HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) score takes two simple blood measurements, fasting insulin and fasting glucose, and combines them into a single number that estimates how well your cells are responding to insulin. The higher the score, the harder your body is working to keep blood sugar under control, and the more likely it is that insulin resistance has taken hold.

What makes HOMA-IR valuable is its ability to quantify a problem that often hides in plain sight. Your fasting glucose can look perfectly normal for years while your pancreas quietly ramps up insulin production to compensate for cells that are becoming deaf to its signal. HOMA-IR captures both sides of that equation at once. A normal glucose paired with a high insulin, or a mildly elevated glucose paired with a modestly high insulin, will both push the score upward, flagging a metabolic problem that neither number would reveal on its own.

How the Score Is Calculated

The formula is straightforward: multiply your fasting insulin level (in μU/mL) by your fasting glucose (in mg/dL), then divide by 405. If your lab reports glucose in mmol/L, the divisor is 22.5 instead. Only a single fasting blood draw is needed, which is one reason HOMA-IR has become so widely used in both research and clinical practice.

The math reflects a basic physiological relationship. In a healthy body, low fasting glucose requires only a small amount of insulin to maintain, producing a low HOMA-IR. When cells resist insulin, glucose drifts up and the pancreas compensates by producing more insulin, and the product of those two rising numbers yields a higher score.

What Your Score Means

One important caveat before looking at cutoffs: different laboratories use different methods to measure insulin, and these assay differences can shift your calculated HOMA-IR by as much as 25%. This means a score of 2.0 at one lab might correspond to a score of 2.5 at another. Tracking trends over time using the same lab is more reliable than comparing a single result to a universal threshold.

What this means for you: if your score falls between 1.5 and 2.5, you are in a transitional zone where lifestyle changes have the greatest potential to reverse the trend. A score above 2.5 is a clear signal that insulin resistance is present and warrants action. In population studies, median HOMA-IR values rise in a stepwise fashion: about 1.54 in people without diabetes, 2.00 in those with prediabetes, and 4.00 in those with diabetes.

Body weight influences interpretation. Higher cutoffs may be more appropriate for individuals who are overweight or obese, since these populations tend to have higher baseline HOMA-IR values. In a large Brazilian cohort study, HOMA-IR varied meaningfully by BMI category, reinforcing the importance of interpreting your score in the context of your overall metabolic picture rather than against a single fixed number.

What Moves This Biomarker

Because HOMA-IR is a composite of fasting insulin and fasting glucose, anything that improves your cells' responsiveness to insulin or reduces excess glucose production by the liver will lower your score. The most effective interventions target both sides of the equation simultaneously.

Weight loss is the most powerful driver. Modest weight loss of about 5% of body weight improves insulin sensitivity across the liver, muscle, and fat tissue at the same time. Losing 10% of body weight reduces insulin resistance by roughly 65%, and the improvement tracks more closely with shrinking waist circumference and fat cell size than with total pounds on the scale. This means that where you lose fat matters as much as how much you lose.

Dietary patterns independently improve insulin sensitivity. The Mediterranean diet, centered on olive oil, nuts, vegetables, whole grains, legumes, and fish, improves insulin sensitivity even without caloric restriction and produces superior glucose control compared to low-fat diets in people with diabetes. The DASH, Nordic, and vegetarian dietary patterns also show benefit. Eliminating sugar-sweetened beverages and reducing processed meat intake are among the most consistently recommended changes.

Regular physical activity acutely improves insulin sensitivity with each session and builds lasting benefit over time, even without weight loss. At least 150 minutes per week of moderate-intensity exercise is recommended. Endurance exercise preferentially reduces the visceral (belly) fat that is most closely tied to insulin resistance. Physically active people with abdominal obesity have about half the coronary artery disease risk of their sedentary peers, even at the same weight.

The scale of benefit from lifestyle change is substantial. The Diabetes Prevention Program found that a combination of 7% weight loss and 150 minutes of weekly exercise reduced new diabetes cases by 58% over 2.8 years, outperforming metformin, which achieved a 40% reduction. Even after 10 years, diabetes risk remained 34% lower in the lifestyle group despite some weight regain. The Finnish Diabetes Prevention Study showed that participants who hit all five lifestyle targets had zero new diabetes cases over 7 years of follow-up.

Metformin is the most widely used medication for insulin resistance, primarily working by reducing the liver's glucose output. It is inexpensive, well-tolerated, and backed by decades of clinical data. Pioglitazone directly improves insulin resistance by promoting healthier fat cell function and clearing ectopic fat from organs, though its side effects (fluid retention, weight gain, bone density loss) limit its use.

Newer medication classes offer both metabolic and cardiovascular benefits. SGLT2 inhibitors lower glucose by promoting its excretion through urine and indirectly improve insulin sensitivity while reducing cardiovascular risk by 12 to 26% and kidney disease progression by 24 to 39% over 2 to 5 years. GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists improve insulin secretion, suppress appetite, and produce weight loss exceeding 5% in most people, with many achieving more than 10%. Current guidelines recommend early use of these agents in people with established or high-risk cardiovascular and kidney disease, even before metformin.

Questions This Biomarker Can Answer

• Are my cells becoming resistant to insulin, even though my fasting glucose still looks normal?
• How far along the spectrum from healthy metabolism to prediabetes to diabetes am I right now?
• Is my current diet and exercise routine actually improving my insulin sensitivity over time?
• Is my level of insulin resistance high enough to explain other findings like fatty liver or abnormal cholesterol?
• Am I a candidate for early metabolic intervention before my blood sugar crosses a diagnostic threshold?